These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7972130)

  • 1. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide.
    Sakakura C; Yamaguchi-Iwai Y; Satake M; Bae SC; Takahashi A; Ogawa E; Hagiwara A; Takahashi T; Murakami A; Makino K
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11723-7. PubMed ID: 7972130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
    Miyoshi H; Kozu T; Shimizu K; Enomoto K; Maseki N; Kaneko Y; Kamada N; Ohki M
    EMBO J; 1993 Jul; 12(7):2715-21. PubMed ID: 8334990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21).
    Nucifora G; Rowley JD
    Leuk Lymphoma; 1994 Aug; 14(5-6):353-62. PubMed ID: 7812194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro catalytic activities of DNA/RNA chimeric hammerhead ribozymes against AML1-MTG8 mRNA, a fused gene transcript in acute myeloid leukemia with t(8;21).
    Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H
    Biochimie; 1996; 78(11-12):1067-73. PubMed ID: 9150886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.
    Ohki M
    Semin Cancer Biol; 1993 Dec; 4(6):369-75. PubMed ID: 8142622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts.
    Dunne J; Cullmann C; Ritter M; Soria NM; Drescher B; Debernardi S; Skoulakis S; Hartmann O; Krause M; Krauter J; Neubauer A; Young BD; Heidenreich O
    Oncogene; 2006 Oct; 25(45):6067-78. PubMed ID: 16652140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
    Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
    Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
    Erickson PF; Robinson M; Owens G; Drabkin HA
    Cancer Res; 1994 Apr; 54(7):1782-6. PubMed ID: 8137293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells.
    Heidenreich O; Krauter J; Riehle H; Hadwiger P; John M; Heil G; Vornlocher HP; Nordheim A
    Blood; 2003 Apr; 101(8):3157-63. PubMed ID: 12480707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.
    Era T; Asou N; Kunisada T; Yamasaki H; Asou H; Kamada N; Nishikawa S; Yamaguchi K; Takatsuki K
    Genes Chromosomes Cancer; 1995 May; 13(1):25-33. PubMed ID: 7541640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.
    Bae SC; Ogawa E; Maruyama M; Oka H; Satake M; Shigesada K; Jenkins NA; Gilbert DJ; Copeland NG; Ito Y
    Mol Cell Biol; 1994 May; 14(5):3242-52. PubMed ID: 8164679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.
    Higuchi M; O'Brien D; Kumaravelu P; Lenny N; Yeoh EJ; Downing JR
    Cancer Cell; 2002 Feb; 1(1):63-74. PubMed ID: 12086889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA.
    Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H
    J Cancer Res Clin Oncol; 1996; 122(4):254-6. PubMed ID: 8601580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AML1/ETO fusion protein activates transcription of BCL-2.
    Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.
    Britos-Bray M; Sacchi N; Friedman AD
    Leukemia; 1996 Jun; 10(6):984-90. PubMed ID: 8667656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.